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Introduction {#s1}
============

In 2010, ambient particulate matter (PM) air pollution was ranked as the ninth overall highest attributable burden risk factor and was estimated to cause 3.1 million premature deaths and 3.1% of disability adjusted life years (DALYs) worldwide ([@c32]). Chronic obstructive pulmonary disease (COPD), acute lower respiratory disease (ALRD), and lung cancer accounted for 28% of deaths attributable to ambient air pollution in 2012 ([@c46]). Ambient air pollution is also thought to increase the risk of asthma exacerbation and asthma onset in children and adults ([@c23]).

Respiratory symptoms such as wheezing and shortness of breath are indicators of airway inflammation associated with chronic respiratory diseases such as COPD, emphysema, and asthma, among other conditions ([@c1]). Wheezing is caused by narrowed or compressed lower airways, which leads to turbulent airflow ([@c34]). Shortness of breath is broadly defined as a subjective feeling of breathing discomfort. It can be characterized by a sense of respiratory effort/work, chest tightness, "air hunger"/unsatisfied inspiration, or a combination of these symptoms ([@c36]). Wheezing usually relates to respiratory dysfunction, whereas breathlessness can be caused by cardiac as well as by respiratory dysfunction ([@c6]). Smoking and environmental tobacco smoke are important risk factors for COPD and for asthma development and symptoms ([@c28]; [@c31]). Like cigarette smoke, ambient air pollution is a source of particulate matter exposure, but research on the relationship between air pollution and wheeze and shortness of breath prevalence in adults has largely been inconsistent ([@c7]) despite evidence for air pollution impacts on respiratory mortality and asthma exacerbation ([@c18]; [@c23]).

Ambient air pollution was associated with incident asthma in a follow-up study of never smokers in the Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA) cohort (41 cases) ([@c30]), and authors of a combined longitudinal analysis of six European cohorts (including SAPALDIA) reported weak positive associations between air pollution and the incidence of adult asthma (1,257 cases) ([@c27]). Data collected from $> 8,500$ SAPALDIA participants in 1991 and 2002 suggested that living near a major street or highway was positively associated with attacks of breathlessness in the previous 12 months ([@c3]). Residential ambient air pollutant concentrations were also associated with the prevalence of breathlessness, but not wheeze, in a cross-sectional study of 9,651 adults in the SAPALDIA cohort ([@c48]). However, outdoor air pollution was associated with incident wheeze (1,023 cases) and incident asthma (254 cases) in a longitudinal analysis of a cohort of adult women in the United States ([@c47]), and a study of 2,628 U.S. male veterans reported an association between residential proximity to a major roadway and persistent wheeze during the past year ([@c20]). Lastly, a cross-sectional survey in Netherlands reported that 673 adults living along busy streets were more likely to report shortness of breath during walking, but not wheeze, than 812 adults living along streets in the same neighborhoods that had little traffic ([@c35]). Many of these studies had limited numbers of participants (and cases), resulting in imprecise estimates of associations between air pollution exposures and respiratory health outcomes and in an inability to explore factors that might modify associations.

PM and nitrogen dioxide ($\text{NO}_{2}$) are commonly used as markers of ambient air pollutant exposures for epidemiologic studies. In the context of the BioSHaRE (Biobank Standardisation and Harmonisation for Research Excellence in the European Union) program, we harmonized and combined data from two of Europe's largest population health studies, the Lifelines Cohort Study and Biobank ([@c42]) and UK Biobank ([@c43]), to explore associations of residential PM and $\text{NO}_{2}$ exposures with the prevalence of wheeze and shortness of breath in cohorts as a whole and in potentially vulnerable population subgroups. To our knowledge, this is the largest study of associations between respiratory symptoms and air pollution to date.

Methods {#s2}
=======

Study Populations {#s2.1}
-----------------

Both the Lifelines and UK Biobank cohorts sampled their participants from the general population using general practice registers. Baseline questionnaire and physical measures data were collected from 152,180 adult Lifelines participants (18--93 y of age) during 2006--2013 ([@c42]) and from 502,655 UK Biobank participants (40--69 y of age) during 2006--2010 ([@c43]). The Lifelines cohort was designed to include three generations of study participants. An initial set of participants was identified from general practice patients residing in the three northern-most provinces of Netherlands (Friesland, Groningen, and Drenthe), which are largely rural regions ([@c29]; [@c40]). The initial group of eligible participants comprised adults who were 25--50 y of age who did not have a severe psychiatric or physical illness or a limited life expectancy and who were able to complete the Dutch-language study questionnaire. Participants were asked to identify family members who might also want to participate in the study, and adult residents of the study provinces also could volunteer directly to participate in the study. Individuals were identified and invited to join the UK Biobank cohort via population-based registries such as those held by the National Health Service. Invitations were stratified according to key sociodemographic factors (e.g., age, sex, and postcode areas as a measure of social deprivation), with over-sampling of particular groups to enhance generalizability and to account for the impact of participation rates ([@c43]). UK Biobank study participants lived within approximately 25 miles of one of 22 assessment centers across Scotland, England, and Wales, in mostly urban areas ([@c2]). Full study sampling methods and participant selection criteria have been defined elsewhere ([@c2]; [@c40]; [@c42]; [@c43]). Participants in both studies provided written informed consent at recruitment for broad use of their data by local and international investigators. We submitted research protocols and data access applications to the Lifelines and UK Biobank ethics and scientific review boards and obtained all necessary approvals.

Standardized Air Pollution Data {#s2.2}
-------------------------------

We used annual average concentrations of $\text{NO}_{2}$ and of particulate matter with aerodynamic diameter $< 10\;\mu m$ (${PM}_{10}$), fine particles with diameter $< 2.5\;\mu m$ (${PM}_{2.5}$), and coarse particles with diameter between $2.5\;\mu m$ and $10\;\mu m$ (${PM}_{\text{coarse}}$) at place of residence for the periods 2009--2010 (Lifelines) and 2010--2011 (UK Biobank). These air pollution estimates were generated in the context of the European Study of Cohorts for Air Pollution Effects (ESCAPE) using a standardized land-use regression (LUR) modeling approach. ESCAPE LUR models developed for Netherlands/Belgium and for southeast England (i.e., London and Oxford) were employed for the Lifelines and UK Biobank study areas, respectively. Geographic information systems (GIS)-derived predictor variables were used to model spatial variation of measured annual air pollutant concentrations in each area, and model performance was evaluated using leave-one-out cross-validation (see Tables S1 and S2). Modeled ${PM}_{2.5}$, ${PM}_{10}$, and $\text{NO}_{2}$ performed relatively well in the Netherlands/Belgium area (cross-validation $R^{2} = 61\%$, 60%, and 80%, respectively) and in the southeast England area (cross-validation $R^{2} = 82\%$, 90%, and 89%, respectively). ${PM}_{\text{coarse}}$ cross-validation $R^{2}$ results were lowest in both areas (38% in the Netherlands/Belgium area; 57% in the southeast England area). Details of the ESCAPE LUR model development and validation methodology have been described elsewhere ([@c5]; [@c15]).

For our study, home addresses of Lifelines and UK Biobank participants at the baseline assessment were geocoded and linked to LUR ESCAPE air pollution estimates. Because a significant proportion of UK Biobank participants resided in areas outside the initial southeast England ESCAPE study area, we tested the transferability of the LUR models using historical monitoring data from the United Kingdom's Automatic Urban and Rural Network (AURN) ([@c25]). The southeast England ESCAPE LUR model was applied to all UK AURN site locations, and associations between the LUR-modeled and AURN-measured $\text{NO}_{2}$ and ${PM}_{10}$ concentrations were analyzed by distance bands radiating from the edge of the ESCAPE study area.

Data Harmonization {#s2.3}
------------------

To ensure data compatibility in our project, all respiratory symptoms and covariates used in statistical analyses went through a structured data harmonization process ([@c12]; [@c19]). As a first step, common-format respiratory outcome and confounding variables required for coanalyses were identified, and the possibility for each cohort to generate these variables was determined using information extracted from questionnaires, data dictionaries (i.e., codebooks), and standard operating procedures. Once "target" variables were defined and the harmonization potential was determined, processing algorithms written in the JavaScript programming language were implemented in Opal data harmonization software ([@c13]) to map data collected from each cohort to a common (i.e., harmonized) format. Lastly, to validate the harmonized data sets, we conducted consistency and logic checks to verify counts and distributions of missing data, value ranges, and recoded variables.

Respiratory symptoms were collected through self-administered surveys at the baseline assessments for Lifelines and UK Biobank using different questionnaire assessment items (see Table S3). Both studies collected data on prevalence of wheeze and shortness-of-breath symptoms. Lifelines collected nonperiod-specified prevalence of wheeze ("Have you had wheezing or whistling in your chest at any time?"), wheezing without a cold ("Have you had this wheezing or whistling when you did not have a cold?"), and wheezing combined with shortness of breath ("Have you been at all breathless when the wheezing noise was present?"). UK Biobank collected information on wheezing in the last year ("In the last year, have you ever had wheeze or whistling in the chest?"). Lifelines participants reported shortness of breath at rest, whereas the UK Biobank questionnaire asked about shortness of breath while walking on level ground. Neither cohort included a recall time period for shortness of breath, and only $\sim 35\%$ of UK Biobank participants had data for this question because it was not added to the baseline survey until 2009. To account for heterogeneity of study-specific assessment items, the harmonized wheeze and shortness-of-breath symptom variables were respectively defined as follows: "presence of wheezing symptoms in the past year or more" and "shortness of breath at rest or when walking on level ground" (see Table S4).

We identified sociodemographic and behavioral risk factors to include as potential confounders and for exploring subgroups of vulnerability through literature review and based on data collected from each cohort (see Table S3). Common-format baseline assessment variables for age, sex, body mass index (BMI) (derived from measured height and weight), household income, highest level of education attained, current passive smoking exposure, and smoking status were defined and harmonized across cohorts (Table S4). For example, we performed the following procedures to derive a common-format variable for disposable household income. First, we derived a net annual household income variable for each cohort. For Lifelines, this variable was based on responses to a question about average monthly household income after taxes. For UK Biobank participants, we adjusted self-reported information on gross annual household income to reflect net income by subtracting estimates of participants' annual tax payments, which were obtained from the UK Government Web Archive ([@c11]). Next, we used data from the Organisation for Economic Co-operation and Development (OECD) (<http://stats.oecd.org/>) to derive a dichotomous income variable defined as "less than or equal to" or "greater than" the country-specific net mean household income for the United Kingdom (20,585 GBP) and Netherlands (25,600 EUR) in 2010.

Statistical Analysis {#s2.4}
--------------------

Harmonized data were analyzed using the DataSHIELD federated analysis method ([@c21]; [@c45]). DataSHIELD involves setting up secure servers hosting harmonized data in geographically dispersed research centers and allowing a central analysis computer to conduct remote statistical analyses of individual-level data without the need to physically pool the data. DataSHIELD relies on three main components, all of which are open-source and freely available: Opal data management and harmonization software ([@c13]), the R statistical programming environment (version 3.3.2; R Development Core Team), and DataSHIELD-specific R packages. For this project, harmonized data sets were hosted on separate servers at the University Medical Center Groningen in Netherlands (Lifelines data) and the Research Institute of the McGill University Health Centre in Canada (UK Biobank data). For an in-depth description of DataSHIELD implementation in the BioSHaRE project, see Gaye et al. ([@c21]).

We used separate logistic regression models to estimate associations between annual average exposures to ${PM}_{2.5}$, ${PM}_{\text{coarse}}$, ${PM}_{10}$, and $\text{NO}_{2}$ at each participant's residence and self-reported wheezing (in the last year for UK Biobank, at any time for Lifelines; yes/no) and shortness of breath (when walking on level ground for UK Biobank, at rest for Lifelines, with no time period specified for either study; yes/no). For each respiratory symptom, we conducted pooled and study-specific logistic regression models in sequential stages, gradually adjusting for potential confounders to better examine their impact on effect estimates. To facilitate comparisons, these models were restricted to participants with data for all covariates in the fully adjusted model. A first minimally adjusted model included age as a continuous variable and sex (male/female) as confounders. In a second model, we further adjusted for BMI (kilograms per meter squared) \[as normal ($\text{BMI} < 25$), overweight ($\text{BMI} = 25$ to $< 30$), or obese ($\text{BMI} \geq 30$), where BMI was calculated from objectively assessed height and weight\], highest level of education attained (less than or equal to secondary education/greater than postsecondary education), and annual net household income (less than or equal to/greater than the country-specific mean for disposable household income in 2010). The fully adjusted model added smoking status (nonsmoker/past smoker/current smoker) and passive smoking (not exposed at home or work/exposed) to the second model. All pooled models also included a study indicator variable. Using the fully adjusted model, we conducted sensitivity analyses by restricting analyses to study particpants living at the same (baseline) address for $\geq 5\,\text{years}$ and $\geq 10\,\text{years}$. We also conducted two-pollutant models by adding $\text{NO}_{2}$ as a confounder to the fully adjusted PM regression models and adding ${PM}_{2.5}$ as a confounder to the $\text{NO}_{2}$ model. We also explored the prevalence of wheeze and shortness of breath according to smoking status and passive smoking exposure to investigate the accuracy of symptom reporting, assuming that individuals exposed to tobacco smoke would have higher symptom prevalence.

Using the third fully adjusted model, we carried out subgroup analyses and tests for interaction to explore whether associations with residential air pollution exposure differed between individuals with different characteristics. Analyses stratified according to age ($< 65$ vs. $\geq 65$ y), sex, smoking status (never smoked vs. current/former smokers), household income ($\leq \text{country} - \text{specific}\,\text{mean}\,\text{disposable}\,\text{household}\,\text{income}$ vs. $> \text{country} - \text{specific}\,\text{mean}\,\text{disposable}\,\text{household}\,\text{income}$), obesity status \[obese ($\text{BMI} \geq 30{\,{kg}/m}^{2}$) vs. nonobese\], and self-reported asthma status ("ever had asthma" vs. "never had asthma") were performed. We tested potential effect modification by including interaction terms in study-specific and pooled analyses. Given potential confounding due to differences in the effects of subgroup variables on respiratory symptoms across studies, we added a second interaction term between the study indicator variable and the respective subgroup variable to the pooled model. Based on the existing literature, we hypothesized increased susceptibility to air pollution among the elderly, smokers, lower-income individuals, obese individuals, and individuals with asthma. Results were considered statistically significant at a level of $p < 0.05$ throughout.

Results {#s3}
=======

When compared with historical monitoring data, the southeast England ESCAPE $\text{NO}_{2}$ model predicted concentrations reasonably well ($R^{2} = 0.67$) across the United Kingdom going back to 2006. For ${PM}_{10}$, the LUR model predicted concentrations moderately well up to $400\;{km}$ away from the initial ESCAPE study area ($R^{2} = 0.53$). All PM analyses were therefore restricted to UK Biobank residential addresses within $400\;{km}$ of the southeast England area.

[Figure 1](#f1){ref-type="fig"} shows flow diagrams outlining study populations, exclusions, and missing data. By the time of the present study, the home addresses of 82,959 (54.5%) of the 152,180 participants had not yet been geocoded by Lifelines data managers (geocoding was performed in the order of participant recruitment). For UK Biobank, 7,393 (1.5%) of the 502,655 residential addresses could not be geocoded. An additional 33,934 residential addresses were excluded from all PM measures because they were farther than $400\;{km}$ away from the ESCAPE monitoring area in southeast England. Residential $\text{NO}_{2}$ and PM exposure estimates were therefore available for 495,262 and 461,328 UK Biobank participants, respectively. The household income variable was missing for 17% of Lifelines participants and for 15% of UK Biobank participants, and 16% of UK Biobank participants had no data for the passive smoking exposure variable. Finally, only 35% of UK Biobank participants had data for shortness of breath because this item was added to the baseline survey late in the recruitment phase (i.e., as of 2009).

![Lifelines and UK Biobank study population flow diagram. Note: $\text{NO}_{2}$, nitrogen dioxide; PM, particulate matter. ^1^By the time of this study, home addresses of 82,959 participants had not yet been geocoded by Lifelines data managers ^2^Residential addresses of 33,934 UK Biobank participants were excluded for all PM measures because they were farther than $400\;{km}$ away from the original European Study of Cohorts for Air Pollution Effects (ESCAPE) monitoring area in southeast England. ^3^Only 35% of UK Biobank subjects had data for shortness of breath because it was added to the baseline survey late in the recruitment phase (i.e., as of 2009).](EHP1353_f1){#f1}

Population characteristics and respiratory symptom prevalence for each cohort are presented in [Table 1](#t1){ref-type="table"}. Women comprised 57 and 53% of the Lifelines and UK Biobank participants, respectively. On average, UK Biobank participants were older, had higher BMI, and had lower educational attainment than Lifelines participants. The mean household income levels were comparable across study populations. There was a higher proportion of current smokers and of individuals exposed to secondhand smoke in Lifelines than in UK Biobank. The prevalence of self-reported respiratory symptoms was approximately the same across cohorts, with 1 in 5 participants reporting wheeze and 1 in 10 reporting shortness of breath. Pooled data showed the prevalence of wheeze was higher in former smokers (20.93%) and current smokers (27.08%) than in never smokers (16.43%), and it was higher in those exposed versus not exposed to passive smoke (23.84% vs. 17.22%) (see Table S5). Shortness of breath was also more common in former and current smokers (11.07% and 11.52%, respectively) than in never smokers (8.85%) and in those exposed versus not exposed to passive smoke (13.45% vs. 8.8%). These patterns were also evident for the individual cohorts (see Table S5).

###### 

Population characteristics and respiratory symptom prevalence.

Table 1 lists characteristics in the first column. The corresponding values for Lifelines (n equals 52064); UK Biobank, wheeze and N O 2 analyses (n equals 350639); and UK Biobank, shortness of breath and N O 2 analyses (n equals 121550 are listed in the other columns.

  Characteristic                                                    Lifelines         UK Biobank        UK Biobank
  ----------------------------------------------------------------- ----------------- ----------------- ----------------
  Male, % ($n$)                                                     43.2 (22,487)     47.3 (165,717)    47.3 (57,486)
  Female, % ($n$)                                                   56.8 (29,577)     52.7 (184,922)    52.7 (64,064)
  Age, $\text{mean} \pm \text{SD}$                                  $42.6 \pm 11.5$   $56.2 \pm 8.1$    $56.5 \pm 8.1$
  Age, % ($n$)                                                                                           
   $< 65\; y$                                                       96.5 (50,233)     82.5 (289,278)    81.2 (98,689)
   $\geq 65\; y$                                                    3.5 (1,831)       17.5 (61,361)     18.8 (22,861)
  BMI, % ($n$)                                                                                           
   Normal ($< 25{\,{kg}/m}^{2}$)                                    47.4 (24,650)     33.3 (116,585)    33.5 (40,767)
   Overweight ($25–29.9{\,{kg}/m}^{2}$)                             38.7 (20,146)     43 (150,657)      42.6 (51,735)
   Obese ( $\geq 30{\,{kg}/m}^{2}$)                                 14 (7,268)        23.8 (83,397)     23.9 (29,048)
  Education level, % ($n$)                                                                               
   Secondary education or lower, % ($n$)                            24.9 (12,936)     35.3 (123,925)    34.3 (41,676)
   Postsecondary education, % ($n$)                                 75.1 (39,128)     64.7 (226,714)    65.7 (79,874)
  Household income, % ($n$)                                                                              
   Mean or below mean country-specific net disposable income        48.4 (25,215)     45.2 (158,600)    45.2 (54,903)
   Higher than mean country-specific net disposable income          51.6 (26,849)     54.8 (192,039)    54.8 (66,647)
  Smoking status, % ($n$)                                                                                
   Current smoker                                                   23.7 (12,345)     3 (10,453)        3 (3,670)
   Former smoker                                                    30.4 (15,813)     38.1 (133,703)    38 (46,191)
   Never smoker                                                     45.9 (23,960)     58.9 (206,483)    59 (71,689)
  Passive smoking exposure, % ($n$)                                                                      
   Not exposed to secondhand smoke at home or at work               73.5 (38,264)     77.74 (272,604)   77.9 (94,708)
   Exposed to secondhand smoke at home or at work                   26.5 (13,800)     22.26 (78,035)    22.1 (26,842)
  Wheeze, % ($n$)                                                                                        
   Has not had wheeze symptoms                                      79.7 (41,466)     81.6 (286,276)    ---
   Has had wheeze symptoms                                          20.4 (10,596)     18.4 (64,363)     ---
  Shortness of breath, %[^*a*^](#t1n1){ref-type="table-fn"} ($n$)                                        
   Has not had shortness of breath symptoms                         90 (46,859)       ---               90.2 (109,584)
   Has had shortness of breath symptoms                             10 (5,205)        ---               9.8 (11,966)
  Asthma, %[^*b*^](#t1n2){ref-type="table-fn"} ($n$)                                                     
   Has had asthma                                                   8.1 (4,203)       11.6 (40,680)     11.5 (13,967)
   Has not had asthma                                               91.9 (47,686)     88.4 (309,729)    88.5 (107,495)

Note: For participants with complete data in fully adjusted model for age, sex, BMI, income, education, smoking status, passive smoking exposure. ---, UK Biobank wheeze prevalence shown in second data column and shortness of breath prevalence shown in third data column; BMI, body mass index; SD, standard deviation.

Only 35% of UK Biobank subjects had data for shortness of breath because it was added to the baseline survey late in the recruitment phase (i.e., as of 2009).

An additional 175 participants had missing data for the asthma status variable in Lifelines. In the UK Biobank, 230 participants and 88 participants had missing data for asthma status for wheeze and $\text{NO}_{2}$ analyses and shortness of breath and $\text{NO}_{2}$ analyses, respectively.

[Table 2](#t2){ref-type="table"} presents descriptive statistics for air pollutants. On average, Lifelines participants were exposed to higher PM and lower $\text{NO}_{2}$ concentrations than UK Biobank participants. For all air pollutants, the UK Biobank study area had a wider range. In both studies, annual mean concentrations of ${PM}_{10}$ were highly correlated with ${PM}_{\text{coarse}}$ (Lifelines $r = 0.87$; UK Biobank $r = 0.81$) and ${PM}_{2.5}$ (Lifelines $r = 0.78$; UK Biobank $r = 0.53$). Annual mean $\text{NO}_{2}$ concentrations were highly correlated with ${PM}_{2.5}$ in UK Biobank ($r = 0.87$) but not in Lifelines ($r = 0.42$) and with ${PM}_{\text{coarse}}$ in Lifelines ($r = 0.77$) but not in UK Biobank ($r = 0.19$) ([Table 2](#t2){ref-type="table"}).

###### 

European Study of Cohorts for Air Pollution Effects (ESCAPE)-based annual average air pollution concentrations at place of residence for the periods 2009--2010 (Lifelines) and 2010--2011 (UK Biobank) in micrograms per cubic meter and correlation matrix.

Table 2 lists pollutants in the first column. The corresponding values of mean (SD); 5th, 50th and 95th percentiles; correlation coefficients (r) of PM sub 2.5, PM sub 10, PM sub coarse, and N O sub 2 are listed in the other columns separately.

  Pollutant                $\text{mean} \pm \text{SD}$   Percentiles   Correlation coefficients (*r*)                               
  ------------------------ ----------------------------- ------------- -------------------------------- ------- ----- ------ ------ ------
  ${PM}_{2.5}$                                                                                                                       
   Pooled                  $10.72 \pm 0.98$              9.22          10.66                            12.39   ---   ---    ---    ---
   Lifelines               $15.55 \pm 0.36$              15.27         15.45                            16.25   1     0.78   0.37   0.42
   UK Biobank              $9.95 \pm 1.04$               8.26          9.90                             11.78   1     0.53   0.21   0.87
  ${PM}_{10}$                                                                                                                        
   Pooled                  $17.29 \pm 1.78$              14.55         17.06                            20.92         ---    ---    ---
   Lifelines               $24.23 \pm 0.68$              23.73         23.95                            25.49         1      0.87   0.74
   UK Biobank              $16.18 \pm 1.90$              13.08         16.00                            20.19         1      0.81   0.50
  ${PM}_{\text{coarse}}$                                                                                                             
   Pooled                  $6.73 \pm 0.85$               6.00          6.43                             9.12                 ---    ---
   Lifelines               $8.68 \pm 0.46$               8.29          8.52                             9.60                 1      0.77
   UK Biobank              $6.41 \pm 0.90$               5.63          6.10                             9.04                 1      0.19
  $\text{NO}_{2}$                                                                                                                    
   Pooled                  $25.45 \pm 7.13$              14.40         24.35                            36.93                       ---
   Lifelines               $16.48 \pm 3.78$              11.93         15.68                            23.38                       1
   UK Biobank              $26.28 \pm 7.53$              14.79         25.74                            39.09                       1

Note: For participants with complete data for wheeze, age, sex, BMI, income, education, smoking status, passive smoking exposure (Lifelines $n = 52,062$; UK Biobank $n = 325,892$). ---, pooled correlation coefficients not performed; BMI, body mass index; $\text{NO}_{2}$, nitrogen dioxide; ${PM}_{2.5}$, particulate matter with aerodynamic diameter $< 2.5\;\mu m$; ${PM}_{10}$, particulate matter with aerodynamic diameter $< 10\;\mu m$; ${PM}_{\text{coarse}}$, particulate matter with aerodynamic diameter $2.5–10\;\mu m$; SD, standard deviation.

The addition of confounders between pooled logistic regression models 1 through 3 gradually reduced the size of associations between air pollutants and respiratory symptoms (see Table S6) for both addition of socioeconomic status (SES) and BMI variables (model 1 to 2) and for smoking variables (model 2 to 3). The relative degree of attenuation was greater for wheeze than for shortness of breath, although ${PM}_{2.5}$ and shortness of breath showed the largest absolute change in the odds ratio (OR) from the minimally adjusted OR of 2.10 (model 1) to 1.69 (model 2) to 1.61 (model 3). Fully adjusted pooled and cohort-specific results are shown in [Table 3](#t3){ref-type="table"}. In the pooled analyses, exposure to ${PM}_{2.5}$ was positively associated with wheeze \[$\text{OR} = 1.16$ per $5\;\mu g/m³$ (95% CI: 1.11, 1.21)\] and shortness of breath \[$\text{OR} = 1.61$ per $5\;\mu g/m³$ (95% CI: 1.45, 1.78)\]. ${PM}_{\text{coarse}}$ exposure showed a positive nonsignificant association with wheeze prevalence \[$\text{OR} = 1.05$ per $5\;\mu g/m³$ (95% CI: 1.00, 1.10)\] and a statistically significant association with shortness-of-breath symptoms \[$\text{OR} = 1.28$ per $5\;\mu g/m³$ (95% CI: 1.15, 1.42)\]. Residential exposure to $\text{NO}_{2}$ also showed significant associations with both wheeze and shortness of breath.

###### 

Logistic regression model estimates of associations between annual average air pollution exposures at the baseline residence and respiratory symptoms for fully adjusted single-pollutant models (by cohort and pooled) and for pooled two-pollutant models.

Table 3 lists exposure and outcome in the first column. The corresponding number of cases or non cases and O R (95 percent confidence intervals) for the Lifelines, UK Biobank, pooled and pooled two-pollutant model are listed in the other columns separately.

  Exposure and outcome                                  Lifelines[^*a*^](#t3n2){ref-type="table-fn"}   UK Biobank[^*a*^](#t3n2){ref-type="table-fn"}         Pooled[^*a*^](#t3n2){ref-type="table-fn"}   Pooled two-pollutant model[^*b*^](#t3n3){ref-type="table-fn"}^,^[^*c*^](#t3n4){ref-type="table-fn"}                                                                                           
  ----------------------------------------------------- ---------------------------------------------- ----------------------------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------- ----------------------------------------------------- ---------------- -----------------------------------------------------
  Wheeze                                                                                                                                                                                                                                                                                                                                                                                                
  ~  ~${PM}_{2.5}$ (per $5\,{\mu g/m}^{3}$)             10,596/41,466                                  1.51 (1.12, 2.03)[^\*^](#t3n1){ref-type="table-fn"}   60,184/265,708                              1.15 (1.10, 1.20)[^\*^](#t3n1){ref-type="table-fn"}                                                   70,780/307,174   1.16 (1.11, 1.21)[^\*^](#t3n1){ref-type="table-fn"}   70,780/307,174   1.22 (1.12, 1.32)[^\*^](#t3n1){ref-type="table-fn"}
  ~  ~${PM}_{10}$ (per $5\,{\mu g/m}^{3}$)              10,596/41,466                                  1.20 (1.02, 1.41)[^\*^](#t3n1){ref-type="table-fn"}   60,184/265,708                              1.02 (1.00, 1.05)[^\*^](#t3n1){ref-type="table-fn"}                                                   70,780/307,174   1.03 (1.01, 1.05)[^\*^](#t3n1){ref-type="table-fn"}   70,780/307,174   1.00 (0.97, 1.03)
  ~  ~${PM}_{\text{coarse}}$ (per $5\,{\mu g/m}^{3}$)   10,596/41,466                                  1.15 (0.90, 1.46)                                     60,184/265,708                              1.04 (0.98, 1.09)                                                                                     70,780/307,174   1.05 (1.00, 1.10)                                     70,780/307,174   1.02 (0.97, 1.07)
  ~  ~$\text{NO}_{2}$ (per $10\,{\mu g/m}^{3}$)         10,596/41466                                   1.11 (1.05, 1.18)[^\*^](#t3n1){ref-type="table-fn"}   64,363/286,276                              1.02 (1.01, 1.03)[^\*^](#t3n1){ref-type="table-fn"}                                                   74,959/327,742   1.03 (1.02, 1.04)[^\*^](#t3n1){ref-type="table-fn"}   70,780/307,174   0.98 (0.96, 1.01)
  Shortness of breath                                                                                                                                                                                                                                                                                                                                                                                   
  ~  ~${PM}_{2.5}$ (per $5\,{\mu g/m}^{3}$)             5,205/46,859                                   1.07 (0.72, 1.58)                                     11,958/109,538                              1.61 (1.44, 1.79)[^\*^](#t3n1){ref-type="table-fn"}                                                   17,163/156,397   1.61 (1.45, 1.78)[^\*^](#t3n1){ref-type="table-fn"}   17,163/156,397   1.04 (0.89, 1.23)
  ~  ~${PM}_{10}$ (per $5\,{\mu g/m}^{3}$)              5,205/46,859                                   1.30 (1.06, 1.60)[^\*^](#t3n1){ref-type="table-fn"}   11,958/109,538                              1.17 (1.11, 1.24)[^\*^](#t3n1){ref-type="table-fn"}                                                   17,163/156,397   1.20 (1.14, 1.27)[^\*^](#t3n1){ref-type="table-fn"}   17,163/156,397   1.04 (0.97, 1.10)
  ~  ~${PM}_{\text{coarse}}$ (per $5\,{\mu g/m}^{3}$)   5,205/46,859                                   1.73 (1.28, 2.35)[^\*^](#t3n1){ref-type="table-fn"}   11,958/109,538                              1.15 (1.03, 1.29)[^\*^](#t3n1){ref-type="table-fn"}                                                   17,163/156,397   1.28 (1.15, 1.42)[^\*^](#t3n1){ref-type="table-fn"}   17,163/156,397   1.08 (0.97, 1.21)
  ~  ~$\text{NO}_{2}$ (per $10\,{\mu g/m}^{3}$)         5,205/46,859                                   1.20 (1.11, 1.29)[^\*^](#t3n1){ref-type="table-fn"}   11,966/109,584                              1.14 (1.11, 1.17)[^\*^](#t3n1){ref-type="table-fn"}                                                   17,171/156,443   1.16 (1.13, 1.19)[^\*^](#t3n1){ref-type="table-fn"}   17,163/156,397   1.15 (1.10, 1.19)[^\*^](#t3n1){ref-type="table-fn"}

Note: CI, confidence interval; $\text{NO}_{2}$, nitrogen dioxide; OR, odds ratio; ${PM}_{2.5}$, particulate matter with aerodynamic diameter $< 2.5\;\mu m$; ${PM}_{10}$, particulate matter with aerodynamic diameter $< 10\;\mu m$; ${PM}_{\text{coarse}}$, particulate matter with aerodynamic diameter $2.5–10\;\mu m$; SD, standard deviation.

$p < 0.05$.

Adjusted for age (continuous), sex, body mass index (normal, overweight, or obese), household income (annual net income $\leq$ or $>$ the country-specific mean for 2010), education level ($\leq$ secondary or postsecondary), smoking status (never, former, or current), passive smoking exposure (none or any), and cohort (Lifelines or UK Biobank).

Pooled models also include an indicator term for the study (Lifelines or UK Biobank).

Two-pollutant models for ${PM}_{2.5}$, ${PM}_{10}$, and ${PM}_{\text{coarse}}$ are adjusted for $\text{NO}_{2}$; two-pollutant models for $\text{NO}_{2}$ are adjusted for ${PM}_{2.5}$.

In two-pollutant models, the association between ${PM}_{2.5}$ and wheeze was robust to adjustment for $\text{NO}_{2}$, but the association between ${PM}_{2.5}$ and shortness of breath was not ([Table 3](#t3){ref-type="table"}). Associations of ${PM}_{10}$ and ${PM}_{\text{coarse}}$ were attenuated to the null for both outcomes when adjusted for $\text{NO}_{2}$. The association between $\text{NO}_{2}$ and shortness of breath was not affected by adjustment for ${PM}_{2.5}$, but $\text{NO}_{2}$ was not associated with wheeze after adjustment ([Table 3](#t3){ref-type="table"}). Associations between pollutant exposure at residence and wheeze and shortness of breath were generally unchanged when restricting analyses to participants who lived at the same address for $\geq 5\; y$ and $\geq 10\; y$ (see Table S7).

[Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"} outline pooled subgroup analyses for exposure to ${PM}_{2.5}$ and ${PM}_{\text{coarse}}$, respectively. ${PM}_{2.5}$ exposure was not associated with wheeze in higher-income individuals \[$\text{OR} = 1.02$ (95% CI: 0.96, 1.08) per $5\;\mu g/m³$\] but was associated with wheeze in lower-income participants \[$\text{OR} = 1.30$ (95% CI: 1.22, 1.38); $p - \text{interaction} < 0.001$\]. Moreover, the association between shortness of breath and a $5 - \mu g/m³$ increment in ${PM}_{2.5}$ was significantly higher among individuals from lower-income households \[adjusted $\text{OR} = 1.73$ (95% CI: 1.52, 1.97)\] than among higher-income individuals \[adjusted $\text{OR} = 1.31$ (95% CI: 1.11, 1.55); $p - \text{interaction} = 0.005$\]. Age, smoking status, and asthma status also modified associations between ${PM}_{2.5}$ and wheeze symptoms, with slightly stronger associations for those $\geq 65\,\text{years}$ of age (vs. $< 65$; $p - \text{interaction} = 0.004$), past or current smokers (vs. never smokers; $p - \text{interaction} < 0.001$) and people without asthma (vs. those with asthma; $p - \text{interaction} = 0.005$). With regard to ${PM}_{2.5}$, the association between ${PM}_{\text{coarse}}$ and shortness of breath was stronger for lower-income participants than for higher-income participants \[$\text{OR} = 1.41$ (95% CI: 1.24, 1.61) vs. 1.09 (95% CI: 0.91, 1.30); $p - \text{interaction} = 0.009$\] although there was no clear difference in the association between ${PM}_{\text{coarse}}$ and wheeze according to income. Lastly, ${PM}_{\text{coarse}}$ was associated with shortness of breath among nonobese participants \[$\text{OR} = 1.41$ (95% CI: 1.23, 1.63)\] but not among obese participants \[$\text{OR} = 1.02$ (95% CI: 0.87, 1.20); $p - \text{interaction} = 0.002$\].

![Adjusted odds ratios \[and 95% confidence intervals (CIs)\] for respiratory symptoms in association with a $5{- \mu g/m}^{3}$ increase in ambient particulate matter with aerodynamic diameter $< 2.5\;\mu m$ (${PM}_{2.5}$) at participant residences among population subgroups based on pooled data from the Lifelines and UK Biobank cohorts. Logistic regression model adjusted for age (continuous), sex, body mass index (BMI) (normal, overweight, or obese), household income (annual net income $\leq$ or $>$ the country-specific mean for 2010), education level ($\leq$ secondary or postsecondary), smoking status (never, former, or current), passive smoking exposure (none/any), and cohort (Lifelines/UK Biobank). Interaction *p*-values are Wald *p*-values for product interaction terms between air pollutants and stratification variables. Non-italic *p*-values (top), wheeze symptoms; Italic *p*-values (bottom), shortness-of-breath symptoms.](EHP1353_f2){#f2}

![Adjusted odds ratios \[and 95% confidence intervals (CIs)\] for respiratory symptoms in association with a $5{- \mu g/m}^{3}$ increase in ambient particulate matter with aerodynamic diameter $2.5–10\;\mu m$ (${PM}_{\text{coarse}}$ at participant residences among population subgroups based on pooled data from the Lifelines and UK Biobank cohorts. Logistic regression model adjusted for age (continuous), sex, body mass index (BMI) (normal, overweight, or obese), household income (annual net income $\leq$ or $>$ the country-specific mean for 2010), education level ($\leq$ secondary or postsecondary), smoking status (never, former, or current), passive smoking exposure (none/any), and cohort (Lifelines/UK Biobank). Interaction *p*-values are Wald *p*-values for product interaction terms between air pollutants and stratification variables. Non-italic *p*-values (top), wheeze symptoms; Italic *p*-values (bottom), shortness-of-breath symptoms.](EHP1353_f3){#f3}

Both ${PM}_{10}$ and $\text{NO}_{2}$ were associated with wheeze in lower-income individuals but not in higher-income participants (see Figures S1 and S2). Associations between $\text{NO}_{2}$ (but not ${PM}_{10}$) and shortness of breath were also significantly stronger for lower-income individuals than for higher-income participants (see Figures S1 and S2). Lastly, interaction for obesity status was observed for ${PM}_{10}$ and $\text{NO}_{2}$ associations with shortness of breath, with nonobese participants showing significantly stronger associations.

Discussion {#s4}
==========

In this pooled study, we found statistically significant associations between mean annual PM and $\text{NO}_{2}$ exposure and self-reported wheeze and shortness-of-breath symptoms. The strongest estimated associations were between fine particulate matter and self-reported shortness-of-breath symptoms, although there was little evidence of an association after adjustment for $\text{NO}_{2}$. The use of large biobanks resulted in a large sample size that provided good statistical power to explore potentially vulnerable population subgroups. Our estimates suggested stronger associations of ${PM}_{2.5}$ with both wheeze and shortness-of-breath symptoms, and of ${PM}_{\text{coarse}}$ with shortness of breath, among participants with lower incomes compared with those with higher incomes. Associations between ${PM}_{2.5}$ and wheeze were significantly higher among older versus younger participants, past or current smokers versus never smokers, and people without versus with asthma. In addition, ${PM}_{\text{coarse}}$ was associated with shortness of breath among nonobese participants, but not among obese participants.

A previous longitudinal analysis of data from six European cohorts that also used ESCAPE exposure estimates reported positive but nonsignificant associations of $\text{NO}_{2}$, nitrogen oxides ($\text{NO}_{x}$), and PM exposure metrics with asthma incidence ([@c27]), and another analysis based on data from four of these six cohorts reported nonsignificant positive associations of $\text{NO}_{2}$, $\text{NO}_{x}$, and ${PM}_{10}$ with COPD prevalence and incidence ([@c39]). More recently, significant positive associations were reported for ${PM}_{10}$ and $\text{NO}_{2}$ exposures (estimated using ESCAPE models) with lifetime asthma prevalence (a self-reported history of ever having had asthma) and current asthma (a self-reported history of asthma plus current or recent use of asthma medications) in a combined analysis of data from UK Biobank, Lifelines, and the Norwegian Nord-Trøndelag Health Study (HUNT3) cohorts ([@c9]). Associations between air pollutants and prevalent wheeze based on our analysis of UK Biobank and Lifelines data were similar to those reported by Cai et al. ([@c9]) for lifetime asthma prevalence. Specifically, for a $5 - \mu g/m³$ increase in ${PM}_{2.5}$, we estimated $\text{OR} = 1.16$ (95% CI: 1.11, 1.21) compared with $\text{OR} = 1.11$ (95% CI: 1.07, 1.16); for a $5 - \mu g/m³$ increase in ${PM}_{10}$, we estimated $\text{OR} = 1.03$ (95% CI: 1.01, 1.05) compared with $\text{OR} = 1.04$ (95% CI: 1.01, 1.06); for a $5 - \mu g/m³$ increase in ${PM}_{\text{coarse}}$, we estimated $\text{OR} = 1.05$ (95% CI: 1.00, 1.10) compared with $\text{OR} = 1.04$ (95% CI: 0.99, 1.09); and for a $10 - \mu g/m³$ increase in $\text{NO}_{2}$, we estimated $\text{OR} = 1.03$ (95% CI: 1.02, 1.04) compared with $\text{OR} = 1.02$ (95% CI: 1.01, 1.04) from Cai et al. ([@c9]).

Associations between air pollutants and shortness of breath were stronger than corresponding associations with wheeze in our study population, which might be consistent with cardiovascular effects ([@c14]) rather than (or in addition to) respiratory effects. A previous study of residential ambient air pollutant concentrations in Swiss adults reported associations with the prevalence of breathlessness, but not wheeze ([@c48]), and adults living along busy streets in Netherlands were more likely to report shortness of breath during walking, but not wheeze, than adults living along low-traffic streets in the same neighborhoods ([@c35]). However, these findings may also represent reporting misclassification: although individuals diagnosed with asthma are likely to recognize the symptom of wheeze, the rest of the population might not and therefore might label the symptom as shortness of breath. Wheeze is not always well recognized in the general population. In the seminal International Study of Asthma and Allergies in Childhood (ISAAC), many countries used a video to demonstrate wheezing symptoms without using the word wheezing and asked if the child had these symptoms, as well as using a written questionnaire using the word "wheezing." Results comparing prevalence tertiles determined using the video versus those determined using the written questionnaire were discordant in a third of centers ([@c4]).

Our study provides evidence in line with previous reports that lower household income may be associated with greater impact of particulate matter pollution on respiratory health ([@c44]), which is of concern because lower-SES individuals are potentially more likely to have higher exposures. As shown in a recent neighborhood-level study conducted in the same countries as these cohorts (i.e., Netherlands and the United Kingdom), the highest particulate matter and $\text{NO}_{2}$ concentrations were consistently found in the most deprived areas in both countries ([@c17]). Lower-SES individuals might be more susceptible to health effects of air pollution exposures because of coexposures to other environmental stressors (e.g., housing conditions, occupational exposures) or because of comorbid conditions related to reduced access to health care or to lifestyle, diet, and other factors ([@c33]).

A review of factors associated with increased susceptibility to the health effects of air pollution suggested that older individuals and people with asthma are at increased risk ([@c38]), consistent with our findings. Although some previous studies have reported evidence suggesting that obese people are more susceptible to health effects of air pollution than nonobese people ([@c38]), we estimated stronger associations between ${PM}_{\text{coarse}}$, ${PM}_{10}$, and $\text{NO}_{2}$ and shortness of breath among nonobese individuals than among obese individuals in our study population. A subjective increase in shortness of breath among obese individuals might largely be explained by decreased respiratory muscle function and higher levels of systemic inflammation ([@c10]), and any additional impact of air pollution on breathlessness could be negligible in this subgroup.

Multipollutant modeling has been proposed as a solution to the problem of double counting or overestimating the effects of any one pollutant ([@c26]). In our study, the association between ${PM}_{2.5}$ and wheeze was robust to adjustment for $\text{NO}_{2}$, and the association between $\text{NO}_{2}$ and shortness of breath was robust to adjustment for ${PM}_{2.5}$, whereas other associations were attenuated to the null after adjustment for a second pollutant. However, the two-pollutant model results should be interpreted with caution because of the different sample sizes, the high correlation between pollutants, and the different pollutant correlation structures across the cohorts included in this study.

Fine particulates (i.e., ${PM}_{2.5}$) have been reported to have stronger associations with respiratory or cardiovascular mortality relative to coarse (i.e., ${PM}_{2.5–10}$) particulates ([@c8]; [@c16]). This difference might be explained by a wider diffusion of fine particulates in the respiratory tract and by a stronger systemic inflammatory response. However, ${PM}_{\text{coarse}}$ has been shown to have as strong or stronger short-term effects on COPD, asthma, and respiratory hospital admissions ([@c8]). For wheeze symptoms, we found consistently stronger associations with ${PM}_{2.5}$ than with ${PM}_{\text{coarse}}$ exposure in pooled and study-specific analyses. The association between ${PM}_{\text{coarse}}$ and shortness of breath was stronger than the association between ${PM}_{2.5}$ and shortness of breath in the Lifelines cohort, where participants were asked if they had ever had an attack of shortness of breath during the day when they were at rest. In contrast, the association between ${PM}_{2.5}$ and shortness of breath was stronger than the association between ${PM}_{\text{coarse}}$ and shortness of breath in the UK Biobank cohort, where participants were asked if they had ever had shortness of breath while walking. These divergent results might reflect differences between the study populations in the composition and sources of coarse particles, the data collection instruments used by each cohort, the way in which participants interpreted the questions about shortness of breath, or other factors ([@c22]; [@c24]). Further, whereas the UK Biobank questionnaire collected period-specific wheeze prevalence (i.e., in the last year), the lack of a specified period in the Lifelines assessment item might have led to recall bias. To help overcome such challenges in the future, new studies should make use of internationally validated questionnaires whenever possible. Implementing standardized questionnaires on asthma and COPD respiratory symptoms and risk factors in epidemiological studies would greatly facilitate comparing and pooling data ([@c37]).

A few limitations with regard to exposure assessment should be noted. First, because no information on study participants' work addresses or time-activity patterns was available in either cohort, air pollution exposure was only estimated at the home address. A study that compared exposures estimated with and without accounting for daily mobility in the metropolitan Vancouver, British Columbia area and in southern California found that estimates that did not account for mobility were biased toward the null, with greater bias when the spatial variability of pollution was higher ([@c41]). Second, applying the ESCAPE southeast England LUR models to the larger UK Biobank study area could have led to exposure measurement error. However, LUR models provided good predictions of historical $\text{NO}_{2}$ concentrations across the United Kingdom ($R^{2} = 0.67$) and good predictions of ${PM}_{10}$ concentrations within a $400 - {km}$ radius of the initial ESCAPE study area ($R^{2} = 0.53$) ([@c25]).

Pooled analyses would have been more strongly influenced by data from the UK Biobank cohort than from the Lifelines cohort because of the larger number of UK Biobank observations included in the analyses. Further, although only 45% of total Lifelines participants had been attributed air pollution exposure estimates, we do not expect selection bias to have been a major problem because participant residences were geocoded in chronological order (i.e., in the order of recruitment) rather than according to any given participant characteristic. Residual confounding, exposure and outcome misclassification, and other potential sources of bias are also possible. Finally, given the cross-sectional nature of our analyses, we cannot confirm the temporal relationship between air pollution exposures and the respiratory symptoms in our study population.

Conclusion {#s5}
==========

In conclusion, the findings from our cross-sectional analysis of data from adult cohorts in the United Kingdom and Netherlands add to existing evidence of the adverse effects of ambient air pollution on respiratory health in adults. In addition, differences in associations among population subgroups may reflect differences in susceptibility according to age, SES, and other factors.
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